Patel Sanj K

CHAIRMAN & CEO, DirectorKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Apr 8, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$364K
Net Open-Market Flow
-$364K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 7, 2026Option exercise(M)10K81K
Apr 7, 2026Tax withholding(F)5K$48.94$236K76K
Apr 6, 2026Option exercise(M)7K$10.36$75K7K
Apr 6, 2026Sell(S)7K$50.01$364K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 7, 2026Option exercise(M)10K$00
Apr 6, 2026Option exercise(M)7K$0432K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001532218-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.